David S. Craig, PharmD    
Advanced Practice Pharmacist 
Acute Pain and Supportive Care Medicine
Moffitt Cancer Center 
Tampa, FL

 

Megan R. Prescott, LCSW, ASWPH-C
Lead Palliative Care Social Worker
University of Colorado Hospital
Aurora, CO

 

Elizabeth Horn Prsic, MD       
Associate Professor, Section of Medical Oncology & Hematology 
Yale University
New Haven, CT  

 

Carey Ramirez, DNP, ANP-C, ACHPN    
Director, Advanced Practice Department
Supportive Care Medicine
City of Hope 
Duarte, CA

 

Jessica Vanderlan, PhD    
Clinical Psychologist
Clinical Assistant Professor, Psychiatry 
Siteman Cancer Center 
BJH & Washington University School of Medicine
St. Louis, MO

 

Jeanie Youngwerth, MD, FAAHPM    
Associate Professor of Medicine
Associate Program Director
Colorado Palliative Medicine Fellowship
Director, Palliative Care Service
University of Colorado - Anschutz
Aurora, CO

 

Nicholas Burwick, MD
Academic Associate Professor
Division of Hematology and Oncology
University of Washington
VA Puget Sound Health Care System
Seattle, WA

 

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers, and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

 

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

 

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients 

 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

 

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

 

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

 

The faculty listed below have no relevant financial relationships with ineligible companies to disclose.

 

 

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

 

Nicholas Burwick, MD 
Bristol Myers Squibb: Speaker’s Bureau  
Takeda: Speaker’s Bureau  

 

David S. Craig, PharmD
Patient Centered Outcome Research Institute (PCORI): Research

 

Megan R. Prescott, LCSW, ASWPH-C
Boehringer-Ingelheim (Obesity): Consultant; Speaker’s Bureau
Eli Lilly (Obesity): Speaker’s Bureau
Novo Nordisk (Obesity): Speaker’s Bureau

 

Elizabeth Horn Prsic, MD
Luminate Medical: Consultant

 

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

 

Faculty for this educational activity are required to disclose when a therapy or procedure being discussed is off-label, unlabeled, experimental, or investigational, and to note any limitations of the data presented (e.g., preliminary findings, ongoing research, or expert opinion). 

 

Some faculty may discuss uses of pharmaceutical agents or devices that are not included in U.S. Food and Drug Administration–approved labeling. These discussions are provided solely for educational purposes and should not be construed as a recommendation for any particular use. Learners are encouraged to review full prescribing information for products discussed.

 

This activity is intended for healthcare professionals for educational purposes only. The content reflects information available at the time of development and may not represent the most current evidence, regulatory status, or prescribing information. Participants should consult current package inserts, clinical guidelines, and institutional policies before prescribing medications or making clinical decisions.

 

This activity has been planned and implemented in compliance with applicable accreditation standards to ensure that content is fair, balanced, evidence-based, and free of commercial bias.

 

This educational activity includes content generated with the support of artificial intelligence (AI)/chatbot tools and reviewed by subject-matter experts. It is intended solely for educational purposes and does not provide medical advice, diagnosis, or treatment recommendations. 

 

AI supported content may contain errors or omissions, and it should not be relied upon as a substitute for the independent clinical judgment of qualified healthcare professionals or for patient specific decision making.

Learners are responsible for critically evaluating all information and applying it in accordance with professional standards, current evidence, regulatory requirements, and the laws of their practicing jurisdiction.